NasdaqGS - Nasdaq Real Time Price USD

Indivior PLC (INDV)

Compare

11.99

+0.06

+(0.50%)

At close: January 24 at 4:00:01 PM EST

12.13

+0.14

+(1.17%)

Pre-Market: 7:52:13 AM EST

Great week for Indivior PLC (LON:INDV) institutional investors after losing 23% over the previous year

Key Insights Institutions' substantial holdings in Indivior implies that they have significant influence over the...

Simply Wall St. 6 days ago

INDV
+0.50%
Indivior (LON:INDV) shareholder returns have been enviable, earning 366% in 5 years

For many, the main point of investing in the stock market is to achieve spectacular returns. While the best companies...

Simply Wall St. last month

INDV
+0.50%
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ...

Despite a dip in revenue, Addex Therapeutics Ltd (ADXN) advances its drug development programs and strengthens its financial position through strategic collaborations.

GuruFocus.com 2 months ago

INDV
+0.50%
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Indivior PLC (Nasdaq/LSE: INDV) last week shared results from a randomized, open-label sub-study in opioid-dependent participants seeking treatment, (NCT04995029) that demonstrates rapid initiation (RI) with SUBLOCADE® (buprenorphine extended-release injection) for the treatment of OUD significantly improves treatment retention compared to standard initiation (SI). RI with SUBLOCADE in a single day may reduce barriers to treatment and improve patient retention especially those who frequently inj

PR Newswire 2 months ago

INDV
+0.50%
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior.

PR Newswire 2 months ago

INDV
+0.50%
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Indivior PLC (Nasdaq/LSE: INDV), in recognizing Substance Abuse Prevention Month, provides an update on key findings from the last year that demonstrate the importance of access to medications for the treatment of opioid use disorder (MOUD) and the effectiveness and safety of SUBLOCADE® in the treatment of OUD. These data add to the growing body of evidence that SUBLOCADE can improve outcomes, such as abstinence, retention, and recovery in persons with OUD.

PR Newswire 2 months ago

INDV
+0.50%
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ...

Indivior PLC (INDV) reports a 13% increase in total net revenue and a 62% rise in adjusted operating profit, while navigating competitive pressures and strategic cost reductions.

GuruFocus.com 3 months ago

INDV
+0.50%
Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates

Indivior (INDV) delivered earnings and revenue surprises of 38.46% and 1.57%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

INDV
+0.50%
Indivior Announces Q3 2024 Financial Results

Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.

PR Newswire 3 months ago

INDV
+0.50%
Two Seas Capital LP Increases Stake in Indivior PLC

On October 15, 2024, Two Seas Capital LP (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 400,001 shares of Indivior PLC (NASDAQ:INDV), a specialty drug manufacturing company. This transaction has increased the firm's total holdings in Indivior to 13,030,027 shares, marking a substantial influence on its investment strategy. Two Seas Capital LP (Trades, Portfolio), based at 1 Read Court, New York, NY 10580, is a prominent investment firm known for its strategic positions in the healthcare and utilities sectors.

GuruFocus.com 3 months ago

INDV
+0.50%
Indivior price target lowered to $16 from $20 at Craig-Hallum

Craig-Hallum lowered the firm’s price target on Indivior to $16 from $20 and keeps a Buy rating on the shares. While Q3 pre-released results were relatively in-line and ahead of expectations on the overall top-line, FY24 guidance was revised lower in what the firm calls “a disappointing update.” The company lowering FY24 net revenue guidance was “entirely driven by worsening fundamentals for Sublocade,” notes the analyst, who calls Sublocade “the chief value driver for Indivior.” There is hope f

TipRanks 3 months ago

INDV
+0.50%
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ...

Indivior PLC (INDV) outlines strategic initiatives to bolster SUBLOCADE's market position amidst increased competition and evolving market dynamics.

GuruFocus.com 3 months ago

INDV
+0.50%
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details

Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects third-quarter net revenue of $302 million – $309 million versus the consensus of $289.37 million. Also, Indivior trimmed its FY24 net revenue outlook to $1.125 billion – $1.165 billion (consensus $1.185 billion) from $1.15 billion – $1.215 billion. In particular, the company now expects lower-than-antic

Benzinga 3 months ago

INDV
+0.50%
Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook

PREMIUM
MT Newswires 3 months ago

INDV
+0.50%
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance.

PR Newswire 3 months ago

INDV
+0.50%
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection submitted by Indivior, Inc. has been granted Priority Review designation by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) action date for this submission is set for February 7, 2025.

PR Newswire 3 months ago

INDV
+0.50%
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ...

Series A financing, milestone payments, and strategic partnerships mark a pivotal quarter for Addex Therapeutics Ltd (ADXN).

GuruFocus.com 3 months ago

INDV
+0.50%
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?

Rigel (RIGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 4 months ago

RIGL

INDV
+0.50%
Top 3 Health Care Stocks That May Explode This Month

The most oversold stocks in the health care sector present an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When ...

Benzinga 4 months ago

MRNA

INDV
+0.50%
PGNY
Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder

Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma's announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies.

PR Newswire 4 months ago

INDV
+0.50%

Performance Overview

Return	INDV	FTSE 100
YTD	-1.56%	+4.44%
1-Year	-32.60%	+11.09%
3-Year	+305.07%	+13.54%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Indivior PLC (INDV)

Great week for Indivior PLC (LON:INDV) institutional investors after losing 23% over the previous year

Indivior (LON:INDV) shareholder returns have been enviable, earning 366% in 5 years

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ...

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ...

Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates

Indivior Announces Q3 2024 Financial Results

Two Seas Capital LP Increases Stake in Indivior PLC

Indivior price target lowered to $16 from $20 at Craig-Hallum

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ...

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ...

Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?

Top 3 Health Care Stocks That May Explode This Month

Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder

Performance Overview